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Background: Multidrug resistance and, in particular, carbapenem resistance is spreading worldwide at an alarming
rate, comprehending a variety of bacterial species and causing both nosocomial and community acquired
outbursts. Early and efficient detection of infected patients or colonized carriers are mandatory steps in infection
control and prevention of multidrug resistance diffusion. The latest EUCAST guidelines for detection of
carbapenemase-producing Enterobacteriaceae have set low clinical breakpoints to ensure the maximum detection
sensitivity of positive samples. Current workflows involve an initial screening step for species and resistance pattern
detection, followed by phenotypic and/or genotypic confirmation. The aim of the present study was to assess the
efficiency of six widely used and validated phenotypic assays for the detection of carbapenemases/AmpC in
Enterobacteriaceae, to estimate the best workflow in the routine characterization of Enterobacteriaceae isolates.
Methods: A panel of 108 non-repetitive Enterobacteriaceae isolates with reduced susceptibility to carbapenems was
analyzed by means of 1) Modified Hodge Test, 2) Metallo Beta Lactamase Etest, 3) Double disk test with EDTA, 4) Rosco
Diagnostica KPC and MBL confirm kit (RDCK™), 5) AmpC Etest and 6) Cloxacillin inhibition test. Confirmation and
validation of results was achieved by genotypic analysis.
Results: The most accurate identification of resistance determinants was obtained with the combined disc test (Rosco
Diagnostica KPC and MBL confirm kit) which had to be coupled with the cloxacillin inhibition test for correct detection
of AmpC enzymes. However, in general, phenotypic tests failed to characterize isolates harboring multiple carbapenem
resistance determinants, which were successfully assessed only by PCR-based analysis.
Conclusions: To detect and control the spread of pathogens with complicated resistance patterns, both optimized
phenotypic analysis (i.e. Rosco Diagnostica KPC and MBL confirm kit coupled with the cloxacillin inhibition test) and
genotypic assays are recommended in the routine diagnostic of clinical laboratories.
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Multidrug resistance among Enterobacteriaceae has be-
come a worldwide major public health issue. The most
worrisome emerging resistance feature corresponds to the
production of carbapenem-hydrolysing beta-lactamases
[1]. Carbapenems are considered the last line of effective
therapy available for the treatment of severe infections* Correspondence: sara.richter@unipd.it
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unless otherwise stated.[2,3]; resistance to these agents reduces clinical therapeutic
choices and frequently leads to treatment failure. Carbape-
nemase enzymes include class A carbapenemases (KPC
types), class B or metallo-beta-lactamases (MBLs) (VIM,
IPM, and NDM types), and class D oxacillinases (e.g.,
OXA-48-like enzymes). In addition, decreased susceptibility
to carbapenems in Enterobacteriaceae may be caused by ei-
ther extended spectrum beta-lactamases (ESBLs) or AmpC
enzymes combined with drug decreased permeability, due
to loss of porins [4]. The association of multiple resistance
determinants, comprehending carbapenemase, cephalos-
porinase enzymes and ESBLs, poses a challenge in thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Different phenotypic and molecular screening and confirma-
tory tests have been described [6-8]. Currently, the resistance
detection workflow involves an initial screening step followed
by phenotypic and/or genotypic confirmation [8-10]. The
screening step is based on evaluation of strain susceptibility
to carbapenems, measured as MIC and compared to MIC
values of ATCC control strains. Current EUCAST clinical
breakpoints for the detection of carbapenemase-producing
Enterobacteriaceae are set to 0.5 mg/L for ertapenem and
2 g/ml for meropenem and imipenem, while the screening
cutoff are set to 0.12 mg/L for meropenem and ertapenem
and 1 g/L for imipenem [9,10]. This choice reflects the
presence of carbapenemase producers that poorly express
resistance determinants and would thus be categorized as
susceptible by clinical breakpoints, while they need further
screening for correct identification.
The phenotypic confirmation of carbapenemase produc-
tion is based on the detection of diffusible carbapenemases
(evaluated in the Modified Hodge Test (MHT)) or on in-
hibition of carbapenemase activity, detected in phenotypic
assays based on the synergy between MBL or KPC in-
hibitors and carbapenems [11,12]. The most widely
used inhibitors are the metal-chelating agent EDTA and
dipicolinic acid against MBL, boronic acid for Ambler
class A carbapenemases and cloxacillin against AmpC.
These are used in different formats which include the
double-disk synergy test, the combined disk test, and
carbapenem/carbapenem-EDTA or cefotetan/cefotetan-
cloxacillin Etest strips [13-15]. In contrast, the geno-
typic confirmation is based on PCR-based techniques.
In this work we aimed at establishing the best workflow
based on phenotypic analysis in the routine detection and
characterization of carbapenem resistant Enterobacteria-
ceae isolates. We compared the efficiency of six different
phenotypic assays: 1) MHT, 2) MBL Etest, 3) Double disk
test with EDTA, 4) Rosco Diagnostica KPC and MBL con-
firm kit (RDCK™), 5) AmpC Etest and 6) Cloxacillin inhib-
ition test in detecting resistance determinants on a panel
of Enterobacteriaceae isolates with reduced susceptibility
to carbapenems. Results were validated by comparison
with genotypic data. The RDCK™ was the most reliable
assay in our hands; however, all phenotypic tests failed to
detect multiple carbapenem resistance mechanisms, which
needed to be assessed by genotypic analysis. Therefore,
the optimized workflow to diagnose and control the
spread of pathogens with complicated resistance patterns
must involve both genotypic and phenotypic analysis.
Results
Antimicrobial susceptibility and molecular
characterization of bacterial isolates
One hundred and eight non-repetitive enterobacterial
clinical isolates that showed reduced susceptibility tocarbapenems with MIC values ≥ 0.5 mg/L of imipenem,
meropenem or ertapenem, at the Vitek II analysis, were
chosen for the study. The challenge set of isolates in-
cluded 93 Klebsiella pneumoniae, 2 Klebsiella oxytoca, 7
Enterobacter cloacae, 2 Enterobacter aerogenes, and 4
Escherichia coli.
Molecular characterization was performed on the
complete set of isolates. PCR and real time PCR reactions
were performed as previously described [16-18]. The resist-
ance determinants, i.e. blaKPC, blaVIM, blaOXA-48, blaNDM,
plasmidic AmpC genes and blaCTX-M1-type, were amplified
and sequenced. Genotypic results indicated that the isolates
included 87 KPC-, 5 VIM-, 3 KPC- and VIM-, 1 NDM-1-, 5
OXA-48-, 4 AmpC- and 3 ESBL-positive samples (Table 1).
ESBL-positive sample harbored CTX-M-15. MICs of carba-
penems of the KPC-, VIM-, OXA-48- and NDM-producers
were ≥ 0.5 mg/L. In contrast, the AmpC-positive samples
showed a reduced susceptibility to imipenem and merope-
nem, with MICs ≥ 0.25 mg/L, and slight resistance to erta-
penem with MICs ≥ 4 mg/L. These data confirmed the
necessity to further test isolates with reduced susceptibility,
as indicated in the EUCAST guidelines (Table 1) [9,10].
Moreover, 5 negative control strains, one per species, were
included: they all tested negative for carbapenem resistance
determinants in the molecular assays.
Sensitivity and specificity of selected commercial
phenotypic tests
The panel of genotypically characterized Enterobacteri-
aceae with reduced susceptibility to carbapenems was
next assessed with six different phenotypic detection
methods: 1) Modified Hodge test (MHT), 2) MBL Etest,
3) EDTA-double disk test, 4) Rosco Diagnostica KPC
and MBL confirm kit (RDCK™) 5) AmpC Etest and 6)
cloxacillin-inhibition test. Tests 5) and 6) are normally
used the verify the presence of AmpC in samples dis-
playing lower susceptibility to carbapenems but testing
negative in the carbapenemase specific assays 1)-4). Re-
sults are summarized in Table 2.
1) MHT correctly identified 95/101 carbapenemase pro-
ducers (94% sensitivity, 100% specificity). KPC-positive iso-
lates were all successfully identified (87/87, 100% sensitivity,
100% specificity), while sensitivity lowered when testing
VIM-positive and KPC-/VIM-positive samples. Less than
half OXA-48-positive samples were recognized by MHT,
while the NDM-1 positive sample gave a disturbed edge
of the inhibition zone that did not lead to straightfor-
ward identification of the positive sample. As for the
AmpC-positive Enterobacter spp strains, 3/4 samples
yielded growth patterns of doubt interpretation that could
be erroneously classified as positive. Finally, MHT cor-
rectly reported no positive samples in ESBL-producing
strains, despite their upraised carbapenem MICs, in line
with reports by other authors [19].
Table 1 Resistance phenotypes of the tested enterobacterial isolates and negative controls, expressed as MIC ranges
of carbapenems obtained at the Vitek II






84 K. pneumoniae KPC 4 - > 8 4 - > 16 2 - > 16
2 E. coli KPC ≤ 0,5 - 4 8 1
1 E. cloacae KPC > 8 > 16 > 16
3 K. pneumoniae KPC + VIM > 8 > 16 > 16
3 E. cloacae VIM > 8 > 16 > 16
2 K. oxytoca VIM ≤ 0,5 1- > 16 1- > 16
1 K. pneumoniae NDM > 8 > 16 > 16
3 K. pneumoniae OXA-48 4 - > 8 2 - > 16 1 - 2
1 E. coli OXA-48 1 2 ≤ 0,25
1 E. cloacae OXA-48 2 1 ≤ 0,25
2 E. aerogenes AmpC > 8 > 16 8 - > 16
2 E. cloacae AmpC 4 ≤ 0,25 - 1 ≤ 0,25
2 K. pneumoniae ESBL > 8 1 4
1 E. coli ESBL > 8 > 16 > 16
Controls
NC1 E. coli none ≤ 0,5 ≤ 0,25 ≤ 0,25
NC2 E. cloacae none ≤ 0,5 0,5 ≤ 0,25
NC3 E. aerogenes none ≤ 0,5 2 ≤ 0,25
NC4 K. pneumoniae none ≤ 0,5 ≤ 0,25 ≤ 0,25
NC5 K. oxytoca none ≤ 0,5 0,5 ≤ 0,25
Enterobacterial samples were grouped bases on the species and resistance determinant/s.
NC: negative control.
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test recognized 6/6 VIM- and NDM-positive samples.
However, both assays completely failed to identify the
presence of MBL in isolates harboring both VIM and
KPC, despite the high MICs of carbapenems of these
samples. The inefficacy of synergy tests using a singleTable 2 Comparison of phenotypic and genotypic analysis me
determinants in a panel of 108 carbepenem non-susceptible
MHT Etest M
RD N. ID ND ID
KPC-2/3 87 87 0 0
VIM-1/2 5 4 1 5
KPC-2 plus VIM-1 3 2 1 0
NDM-1 1 0 1 1
OXA-48 5 2 3 0
Total 101 95/101 6/11
Technique sensitivity/specificity Sensitivity 94% Sensitivity
Specificity 100% Specificity
MTH: Modified Hodge Test; DDST: Double Disk Synergy Test; RDCK ™: Rosco Diagnostic
ID: identified; ND: not detected; *in one case the isolate harboring KPC and VIM was m
AmpC- and ESBL-positive strains were not detected by MHT, Etest MBL and EDTA DDS
RDCK™ did not indicated the presence of ESBL determinants as indicated by manufacturinhibitor for the characterization of isolates express-
ing both Ambler class A and B has been previously
reported [20]. Furthermore, the MBL Etest and EDTA
double disk synergy test were tested against the
whole panel of isolates and no false positive result
was recorded.thods for the detection of carbapenem-resistance
Enterobacteriaceae
BL EDTA DDST RDCK™ Molecular tests
ND ID ND ID ND ID ND
87 0 87 87 0 87 0
0 5 0 3 2 5 0
3 0 3 0 3* 3 0
1 0 1 0 1 0
5 0 5 5 0 5 0
6/11 96/101 101/101
54.5% Sensitivity 54.5% Sensitivity 95% Sensitivity 100%
100% Specificity 100% Specificity 99% Specificity 100%
s Confirmation Kit; RD: resistance determinants; N.: number of isolates;
isclassified as OXA-48 producer, in two other cases the results were doubtful.
T while molecular tests correctly identified both AmpC and ESBL determinants.
er’s instructions and misclassified as OXA-48 producer 2 out of 4 AmpC producers.
Bartolini et al. Gut Pathogens 2014, 6:13 Page 4 of 7
http://www.gutpathogens.com/content/6/1/134) RDCK™ correctly pointed out the presence of
carbapenem-hydrolyzing enzymes in 96/101 isolates. In
detail, the commercial phenotypic test indicated the
presence of KPC, NDM-1 and OXA-48, in 93/93 sam-
ples (100% sensitivity, 100% specificity). The assay iden-
tified 3/5 VIM-positive samples, while failed in pointing
out the double positive isolates that harbored both KPC
and VIM. Out of the 4 Enterobacter spp. samples, two
E. cloacae and two E. aerogenes, RDCK™ revealed the
presence of AmpC expression in the two E. aerogenes
samples. The two AmpC-positive E. cloacae samples
tested either negative or suggested the presence of an
OXA-48 like enzyme. Conversely all Enterobacter spp.
samples were found positive for plasmidic AmpC by
PCR analysis. This fact highlights the possibility to ob-
tain false positive or misleading results with the RDCK™
kit. The same outcome was recently reported by other
groups [7,21]. The kit did not recognize the presence of
ESBL overexpression with porin impairment, which is
in accordance with the test guidelines.
5) and 6) The phenotypic identification of AmpC en-
zyme conferring carbapenem resistance was conducted by
means of AmpC Etest and cloxacillin-containing medium.
AmpC Etest correctly identified only 2/4 samples, while
cloxacillin inhibition test succeeded in identifying 4/4
AmpC-positive isolates.
Discussion and conclusions
The massive worldwide spreading of carbapenemase-
producers, mainly Enterobacteriaceae, has forced routine
analysis to elaborate reliable detection methods. High
sensitivity and specificity together with a rapid workflow
has become mandatory to delineate the treatability of
dangerous pathogens and to control and hinder their
spread. The epidemiology of carbapenemases had been
widely discussed as it has become a major health issue,
especially in countries, such as Greece, Israel, USA and
many others, where carbapenemase producers are
becoming endemic [1]. A large variety of carbapenem-
hydrolyzing enzymes has been identified in Gram nega-
tive bacilli [22]. The Ambler class A (KPC-type) and
class B (VIM- and NDM-type) are the most relevant
carbapenemases in the clinic; class D (OXA-48-like) are
gaining increasing importance, due to their recent spread
and to their peculiar hydrolysis profile [23]. Moreover a
particular class of plasmidic cephalosporinases (AmpC,
Ambler class C) displays a slightly extended inducible
hydrolytic activity towards carbapenems and therefore has
to be taken into consideration during putative carbapene-
mase detection and subsequent antimicrobial treatment
[24]. In the present work we analyzed six different pheno-
typic tests for their ability to correctly identify carbapenem
resistance mechanisms, to provide the most accurate, reli-
able and easy to set up workflow for the detection ofcarbapenemase and carbapenem hydrolyzing AmpC pro-
ducers in clinical specimens.
The threshold of susceptibility to the three major car-
bapenems (imipenem, meropenem or ertapenem) was
set to 0.5 mg/L: considering the latest EUCAST docu-
ment on “Detection of resistance mechanisms” [9,10],
the chosen screening cutoff offers a broad and safe
probability of detection of carbapenemase producers. A
similar threshold has been set by other groups (MIC of
meropenem ≥ 0.5 mg/L as point of suspicion of carbape-
nemase production [20]). Although a low threshold
leads to inclusion in routine diagnostic of isolates that
may result negative in subsequent characterization of
carbapenem-resistance, this choice maximizes detection
sensitivity and should be recommended for epidemi-
ology and spreading control purposes. In addition, our
results suggest to take into consideration the MIC of
the three main carbapenems used in the clinical prac-
tice, i.e. imipenem, meropenem and ertapenem, as each
of them displays both positive and negative features: re-
duced screening breakpoints to imipenem and merope-
nem increase sensitivity but decrease specificity of
carbapenemase detection, as the MIC distribution of
the wild-type population is very variable and may be
several times higher than the breakpoint. Meropenem
offers the best compromise between sensitivity and specifi-
city in terms of detection of carbapenemase-producers.
Ertapenem exhibits low efficiency in indicating the pres-
ence of non-KPC class A carbapenemases and in general
low specificity for carbapenemase detection, since AmpC/
ESBL positive Enterobacter spp isolates, have higher MICs
of ertapenem than of imipenem and meropenem [13,25].
To avoid resistance spreading, we would not recommend
setting threshold or screening cutoff higher than those
indicated by EUCAST.
Among the tested phenotypic assays, we found import-
ant differences in terms of sensitivity and specificity. To
summarize, the MHT (1) worked well for the detection of
KPC, while it was not able to consistently recognize
MBLs. In addition, it has been reported that high levels of
expression of AmpC coupled with decreased permeability
may be interpreted as carbapenem hydrolyzing enzyme
and therefore may yield false positive results [19,21]. The
MHT has been the gold standard technique in the past
years [26]; however, the massive spreading of both MBL
and OXA-48-like enzymes, coupled with the diffusion of
Ambler class A carbapenemases in Gram negative bacilli,
such as Proteus spp. and Pseudomonas spp., makes it less
reliable nowadays [27]. The successful detection of MBLs
was mainly achieved by the EDTA inhibition test, using in-
differently Etest strips (2) or the double disk test (3). The
main limit of these assays is that they may fail to detect
positive isolates with low level resistance [26]. Moreover,
in both assays only KPC was detected in samples positive
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less sensitive than the double disk test; on the other hand,
EDTA containing discs are manually prepared which in-
creases the statistical error. The RDCK™ (4) was the best
choice for the phenotypic detection of carbapenemase pro-
ducers which expressed enzymes belonging to Ambler class
A, B, C and D. The latest EUCAST guidelines recommend
the use of this kit in routine diagnostic [9,10]. Results were
achieved within 24 hours from the first identification of
diminished susceptibility to carbapenems at the Vitek II.
However, we found interpretation of results disputable in
the case of OXA-48-like enzymes and AmpCs, which thus
needed to be confirmed by other techniques. Results ob-
tained by this method may be improved introducing temo-
cillin or combining two different inhibitors, such as boronic
acid and dipicolinic acid [7,20].
Other groups have also recommended the improve-
ment of RDCK™ in terms of sensitivity of the merope-
nem/DPA combination, in particular for the detection of
IMP enzymes (IMP-8), and the evaluation of local epi-
demiology prior to utilization of this phenotypic test in
the routine diagnostic [28,29]. The identification of over-
expressed AmpC enzymes, which display a broadened
hydrolysis spectrum conferring carbapenem resistance
[30], resulted sensitive and specific using the cloxacillin-
containing medium (6), as previously reported [13]. In
contrast, the Etest strips (5) lacked sensitivity as they failed
to detect 50% of positive isolates. To note that none of the
tested phenotypic assays was able to detect isolates positive
for two resistance determinants, i.e. KPC and VIM. This
problem has to be taken into serious consideration, since
bacilli with multiple carbapenem resistant mechanisms are
increasingly encountered. Only two studies have so far ad-
dressed this issue reporting that clinical isolates expressing
more than one carbapenemase in association with other
beta-lactamases, such as ESBLs, display composite pheno-
typic resistance profiles that available phenotypic assays are
unable to correctly dissect [7,26]; the EUCAST guidelines
do not thoroughly cover this aspect yet.
On the whole, phenotypic analysis was less reliable
than genotypic characterization in the identification of
carbapenem resistant strains. However, PCR-based mo-
lecular assays have their own limitations: they need ex-
pensive equipment and reagents, and expert personnel
which are not always available to the diagnostic labora-
tory. In addition, primers have to be designed within
low mutation rate regions and the use of specific
primers hinders the identification of novel resistance
genes, possibly reporting false negative results.
Therefore, among phenotypic methods for the detec-
tion of carbapenemase producers, in our hands RDCK™
reported the most reliable results. This method, as indi-
cated in the EUCAST guidelines, should be applied
in the routine screening of all samples with reducedsusceptibility to carbapenems. In case of negative results
in carbapenem non-susceptible strains, further analysis by
means of cloxacillin inhibition test is suggested for the un-
ambiguous detection of AmpC enzymes. In addition, if
RDCK™ gives doubtful results, the simultaneous presence
of two or more carbapenem resistance mechanisms, or an
OXA-48-like enzyme, should be suspected and the mo-
lecular tests are the methods of choice in this instance.
Therefore, where possible, the concomitant use of both
phenotypic and genotypic analysis is highly recommended.
Molecular tests can be applied straightforward to screen
putative infected/colonized patients/carriers in intensive
care or transplant units and immunocompromised pa-
tients. Quickness to achieve results, obtained by PCR-
based methods, is crucial in terms of clinical management,
implementation of infection control measures and for
antibiotic stewardship [31]. In conclusion, to our experi-
ence, the best workflow applicable in routine phenotypic
diagnostics of carbapenem non-susceptible Enterobacteri-
aceae involves the application of the updated EUCAST
clinical breakpoints and the use of RDCK™ as first line ana-
lysis, followed by, in case of doubtful results, AmpC (i.e.
cloxacillin containing medium) and OXA-48 (i.e. evalu-
ation of temocillin resistance) confirmation tests. Molecu-
lar assays are also recommended due to their rapidity and
sensitivity in the characterization of isolates displaying a
complex phenotype, whose identification of resistance




One hundred and eight, non-repeat clinical isolates of
carbapenemase-, AmpC- and ESBLs producing Enterobac-
teriaceae were included in the study. They were collected
in the Microbiology and Virology Unit of the Padua Teach-
ing Hospital from both hospitalized and non-hospitalized
patients. These encompassed Klebsiella spp., Escherichia
coli, and Enterobacter spp.. All these isolates tested non-
susceptible (i.e., intermediate or resistant) to carbapenems
(i.e., MICs of meropenem, imipenem and ertapenem were
at least 0.5 mg/L) as determined by the Vitek II system
(bioMerieux, Marcy l’Etoile, France). Moreover, the disk dif-
fusion test was performed to detect ESBLs (BD BB™ Sensi-
Disk™, Becton Dickinson Italia, Milan, Italy). Five additional
carbapenemase-negative control strains (ATCC strains
number 25922 for E. coli, 700603 for K. pneumoniae,
700324 for K. oxytoca and two clinical samples for E. clo-
acae and E. aerogenes, assessed by molecular analysis) were
also included as negative controls.
Molecular analysis
PCR and real-time PCR amplification were performed
as previously described [16-18]. Bacterial lysates were
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purity plates. DNA was also extracted from stools, when
necessary. Subsequent purity plates were analysed by means
of traditional PCR and gene sequencing for further con-
firmation. The presence of blaKPC, blaVIM, blaOXA-48,
blaNDM, plasmidic AmpC genes and blaCTX-M1-type was in-
vestigated [32,33]. PCR amplicons were sequenced by end-
primers in an ABI3130xl sequencer (Applied Biosystems,
Life Technologies Italia, Milan, Italy) and the obtained se-




Carbapenemase activity assay was performed as previously
reported [26]. In brief, E. coli ATCC 25922 was streaked for
confluent growth on cation-adjusted Mueller-Hinton II
agar plates (Becton Dickinson Italia, Milan, Italy). A disk
saturated with 10 μg of imipenem (Becton Dickinson Italia,
Milan, Italy) was placed in the center of the plate, and each
sample was subsequently streaked from the disk to the edge
of the plate. The presence of a distorted inhibition zone
after overnight incubation was interpreted as a positive re-
sult. Performance quality control strains were included in
each test (the positive control was K. pneumoniae ATCC
BAA-1705, the negative control was K. pneumoniae ATCC
BAA-1706).
EDTA inhibition test
This combination phenotypic detection method was
performed using meropenem and meropenem-EDTA
(292 μg). The stock solution of EDTA was prepared by
dissolving anhydrous EDTA (Sigma-Aldrich, Milan, Italy)
in distilled water at a concentration of 0.1 M. 10 μL of this
solution were dispensed onto meropenem discs (BD BB™
Sensi-Disk™, Becton Dickinson Italia, Milan, Italy). The
discs were then dried and used within 60 min. The test
was performed as a standard diffusion method, using one
disk of meropenem and one containing meropenem and
EDTA. A growth zone difference above 5 mm confirmed
the presence of MBL [34].
Rosco Diagnostica KPC and MBL confirm kit (RDCK™)
This commercial Kit (catalog number 98006) consists
of 4 tablets: tablet A contains meropenem, tablet B con-
tains meropenem and dipicolinic acid (MBL inhibitor),
tablet C contains meropenem and cloxacillin (AmpC in-
hibitor), and tablet D contains meropenem and boronic
acid (KPC inhibitor). The results are interpreted as fol-
lows: the zone of inhibition of tablet A is compared to
the zones of inhibition of each of the carbapenem-plus-
inhibitor tablets (B, C, and D). A growth zone difference
above 5 mm indicates the presence of enzyme activity.
Each tablet indicates one specific resistance mechanism:tablet B points to MBL activity; tablet D reveals KPC ac-
tivity, the association of tablets C and D shows AmpC
activity coupled with porin loss.
Cloxacillin inhibition test
Both cation adjusted and cloxacillin-containing (250 mg/ml)
Mueller-Hinton II agar plates (Becton Dickinson Italia,
Milan, Italy) were inoculated with isolate suspension, as de-
scribed [13]. One cefotaxime (30 μg, BD BB™ Sensi-Disk™)
and one ceftazidime (30 μg, BD BB™ Sensi-Disk™) disk were
placed on both cation adjusted and cloxacillin-containing
agar plates. After overnight incubation, an inhibition zone
above 5 mm in the cloxacillin-containing plate revealed the
presence of AmpC enzymes.
E-test MBL and AmpC: E-tests for detection of MBL
and cefalosporinases AmpC were conducted according
to manufacturer protocol (Etest® MP/MPI and CN/CNI,
bioMerieux, Marcy l’Etoile, France).
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